Drug Profile
Research programme: remyelinating monoclonal antibodies - Acorda Therapeutics/Mayo Clinic
Alternative Names: 94.03; M1 monoclonal antibodies; Remyelinating MAbs; Remyelination programme; SCH79.08; SCH94.03; SCH94.32; sHIgM46Latest Information Update: 09 Apr 2024
Price :
$50
*
At a glance
- Originator Mayo Clinic
- Developer Acorda Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Myelin protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Multiple sclerosis; Spinal cord injuries
Most Recent Events
- 01 Apr 2024 Discontinued - Preclinical for Multiple sclerosis in USA (Parenteral) as company files for bankruptcy
- 01 Apr 2024 Discontinued - Preclinical for Spinal cord injuries in USA (Parenteral) as company files for bankruptcy
- 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA (Parenteral)